Haleon plc

LSE HLN.L

Haleon plc Price to Sales Ratio (P/S) on January 14, 2025: 2.82

Haleon plc Price to Sales Ratio (P/S) is 2.82 on January 14, 2025, a 4.71% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Haleon plc 52-week high Price to Sales Ratio (P/S) is 3.35 on September 27, 2024, which is 18.87% above the current Price to Sales Ratio (P/S).
Haleon plc 52-week low Price to Sales Ratio (P/S) is 2.40 on December 20, 2024, which is -14.96% below the current Price to Sales Ratio (P/S).
Haleon plc average Price to Sales Ratio (P/S) for the last 52 weeks is 2.83.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

LSE: HLN.L

Haleon plc

CEO	Mr. Brian James McNamara
IPO Date	July 18, 2022
Location	United Kingdom
Headquarters	Building 5
Employees	25,408
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods

Description

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Key trends

Past 5 years